Novo takes the plunge in Alzheimer’s
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
